10.7 Palliative Care, Hospice & End-of-Life Management
Key Takeaways
- Specialty palliative care focuses on symptom optimization and quality of life integrated concurrently alongside disease-directed therapies at any stage of advanced cancer, whereas hospice is restricted to certified terminal prognoses of ≤6 months where disease-directed curative intent is foregone.
- Medicare Hospice Benefit certification requires two independent physician attestations that the patient has a terminal illness with a projected life expectancy of 6 months or less if the disease runs its natural course.
- Physician Orders for Life-Sustaining Treatment (POLST/MOLST) convert patient advance directives into actionable, legally binding medical orders actionable by emergency medical services across all care settings.
- Terminal dyspnea is managed first-line with low-dose systemic opioids (e.g., oral or IV morphine) to attenuate brainstem respiratory drive and relieve air hunger, supplemented by oxygen only in the presence of hypoxemia.
- Noisy respiratory secretions ('death rattle') are treated with anticholinergics such as glycopyrrolate or scopolamine, hyperactive terminal delirium is managed with haloperidol, and refractory end-of-life distress may require palliative sedation.
Palliative Care, Hospice & End-of-Life Management
Palliative care and hospice represent specialized medical approaches dedicated to alleviating suffering, optimizing quality of life, and supporting patients and families facing serious or life-threatening malignancies. ASCO guidelines recommend that all patients with advanced solid tumors or high symptom burden receive dedicated specialty palliative care services early in their disease course, within 8 weeks of diagnosis, integrated concurrently with active disease-directed antineoplastic therapy. As disease progression occurs, transitioning to hospice care ensures compassionate, dignity-centered end-of-life support. Advanced Practice Registered Nurses (APRNs) must possess expert competence in distinguishing palliative from hospice care, navigating advance directives and POLST frameworks, and managing complex, distressing end-of-life physical symptoms.
1. Concurrent Palliative Care vs. Hospice Care
While palliative care and hospice share the core philosophy of symptom management and holistic patient-family support, they differ significantly in regulatory structure, timing, and treatment intent.
| Characteristic | Specialty Palliative Care | Hospice Care (Medicare Hospice Benefit) |
|---|---|---|
| Disease Stage / Timing | Initiated at any stage of serious illness (from diagnosis through survivorship or end of life). | Restricted to the terminal phase of disease. |
| Prognostic Criteria | No prognostic restriction (life expectancy can be years). | Requires certification of a terminal prognosis of ≤6 months if the disease runs its normal course. |
| Disease-Directed Therapy | Concurrent: Delivered alongside active disease-directed treatment (chemotherapy, RT, immunotherapy, clinical trials). | Patient foregoes curative/disease-directed antineoplastic treatments, electing comfort-focused care. |
| Payment / Care Setting | Covered by Medicare Part B, Medicaid, private insurance in inpatient, clinic, or home settings. | Specific Medicare Hospice Benefit (Part A) covering comprehensive interdisciplinary team care, meds, and supplies. |
The Medicare Hospice Benefit (MHB) Eligibility Criteria
To enroll in the Medicare Hospice Benefit, the following regulatory requirements must be met:
- Two Physician Certifications: The attending physician and the hospice medical director must certify that the patient is terminally ill with a projected life expectancy of 6 months or less if the disease follows its natural course.
- Election of Comfort Benefit: The patient (or legal healthcare proxy) elects the hospice benefit, signing a statement choosing comfort-focused palliative care and waiving Medicare coverage for curative treatment of the terminal diagnosis.
- Interdisciplinary Team Care: Care is delivered by an interdisciplinary team (physician, APRN, nurse, social worker, chaplain, home health aide, bereavement counselor).
- Benefit Periods: Two initial 90-day benefit periods followed by an unlimited number of 60-day periods, provided the patient is re-certified as terminally ill at the start of each period.
2. Advance Care Planning & POLST / MOLST Frameworks
Advance Care Planning (ACP) is a ongoing process of communication wherein patients articulate their values, goals, and preferences for future medical care.
Legal Advance Directives vs. Medical Orders
- Living Will: A legal document specifying a patient's preferences regarding life-sustaining treatments (e.g., mechanical ventilation, cardiopulmonary resuscitation [CPR], artificial nutrition/hydration) if they become terminally ill or permanently unconscious.
- Healthcare Proxy / Durable Power of Attorney for Healthcare: Designates a surrogate decision-maker to make medical decisions if the patient loses decision-making capacity.
- POLST (Physician Orders for Life-Sustaining Treatment) / MOLST (Medical Orders):
- A actionable, legally binding medical order signed by a licensed clinician (Physician or APRN) and the patient/proxy.
- Translates patient preferences from living wills into specific medical commands (e.g., CPR vs. DNR, Full Treatment vs. Selective Treatment vs. Comfort Measures Only, Intubation vs. Non-invasive ventilation vs. No CPAP).
- Critical Advantage: POLST orders are valid across all healthcare settings (home, nursing facility, emergency medical services [EMS], hospital) and MUST be honored by emergency first responders.
3. End-of-Life Symptom Management Protocols
In the final days and hours of life (imminent death), physical symptoms can fluctuate rapidly, requiring aggressive, proactive APRN pharmacological management.
1. Terminal Dyspnea (Air Hunger)
Terminal dyspnea is one of the most distressing end-of-life symptoms, characterized by a subjective sensation of severe breathlessness.
- Pathophysiology: Disruption between motor respiratory drive from the brainstem and mechanical feedback from pulmonary stretch receptors.
- First-Line Pharmacological Intervention: Systemic Opioids (Oral / Sublingual / IV / Subcutaneous Morphine).
- Mechanism: Opioids reduce the brainstem sensitivity to hypercapnia and hypoxia, decrease central perception of air hunger, and decrease respiratory drive.
- Dosing: In opioid-naive patients, low-dose Morphine (2.5 to 5 mg PO/SL or 1 to 2 mg IV/SC every 2 to 4 hours PRN). In opioid-tolerant patients, increase baseline dose by 25% to 50%.
- Supplemental Oxygen Role: Administer oxygen only if the patient is documented to be hypoxic ($SpO_2 < 90%$). Oxygen does not relieve non-hypoxic dyspnea; a bedside electric fan directing cool air across the trigeminal nerve distribution (V2/V3 face) is equally or more effective.
- Adjunctive Anxiolytics: Benzodiazepines (Lorazepam 0.5–1 mg PO/SL/IV) added if dyspnea is accompanied by severe anxiety/panic.
2. Noisy Respiratory Secretions ("Death Rattle")
Noisy breathing occurring in imminently dying, somnolent patients, caused by the accumulation of salivary and bronchial secretions in the pharynx and trachea due to loss of the swallow reflex.
- First-Line Pharmacological Intervention: Anticholinergic / Antimuscarinic Agents.
- Glycopyrrolate: 0.2 to 0.4 mg IV/SC every 4 hours (or 1 to 2 mg PO/SL). Clinical Advantage: Does not cross the blood-brain barrier; causes minimal central CNS anticholinergic toxicity or delirium.
- Scopolamine (Hyoscine Hydrobromide): Transdermal patch (1.5 mg applied behind ear every 72 hours) or 0.2 to 0.4 mg SC. Crosses the blood-brain barrier (may cause mild sedation).
- Hyoscine Butylbromide: 20 mg SC every 4 hours.
- Non-Pharmacological Actions: Reposition patient to side-lying (lateral decubitus) position with head of bed elevated. Avoid invasive deep nasotracheal suctioning, which causes pain, gagging, tissue trauma, and reflex secretion production.
3. Terminal Delirium & Agitation
Fluctuating disturbance in attention, awareness, and cognition occurring in up to 80% of oncology patients in their final days.
- Classification: Hypoactive (somnolent, withdrawn), Hyperactive (agitated, restless, hallucinating), or Mixed.
- First-Line Pharmacological Intervention: Low-Dose Haloperidol.
- Dosing: 0.5 to 2.0 mg IV, Subcutaneous, or PO/SL every 4 to 6 hours PRN for hyperactive delirium/agitation.
- Second-Line / Atypical Antipsychotics: Olanzapine (2.5–5 mg), Quetiapine (12.5–25 mg), or Risperidone.
- Caution: Avoid single-agent benzodiazepines (lorazepam) in hyperactive delirium without an antipsychotic, as they frequently cause paradoxical worsening of agitation.
4. Refractory Distress & Palliative Sedation
- Palliative Sedation to Unconsciousness (PSU): The monitored administration of sedative medications to induce decreased consciousness or unconsciousness to relieve intractable, refractory physical symptoms (e.g., severe refractory dyspnea, overwhelming pain, catastrophic hemorrhage) when all other palliative measures have failed.
- Pharmacological Agent of Choice: Continuous IV / Subcutaneous Midazolam infusion (or Propofol/Phenobarbital in refractory cases), titrated strictly to symptom relief while continuing baseline opioid analgesia.
A 71-year-old male with Stage IV pancreatic ductal adenocarcinoma and extensive liver metastases is evaluated by the outpatient APRN. The patient expresses a strong desire to focus entirely on quality of life at home and avoid future emergency room visits. His functional status is declining, and his estimated life expectancy is 4 to 5 months. Which option accurately describes the regulatory requirements for enrolling this patient in the Medicare Hospice Benefit?
An 82-year-old female patient with end-stage non-small cell lung cancer enrolled in home hospice care experiences severe acute terminal dyspnea at rest. Her respiratory rate is 32 breaths per minute with intercostal retractions. Oxygen saturation on room air is 93%. What is the first-line pharmacological treatment of choice for the APRN to order?
A 66-year-old male with end-stage metastatic prostate cancer is imminently dying in an inpatient hospice unit. The patient is uncommunicative, and the family is extremely distressed by loud, gurgling respiratory sounds with each breath ('death rattle'). Which intervention should the APRN order as the most appropriate management?